Literature DB >> 21627327

Structure-based fragment hopping for lead optimization using predocked fragment database.

Fang-Yu Lin1, Yufeng J Tseng.   

Abstract

In this work, we describe a structure-based de novo optimization process, called "LeadOp" (short for lead optimization), that decomposes a compound into fragments of different molecular components either by chemical or user-defined rules. Each fragment is evaluated through a predocked fragment database that ranks fragments according to specific fragment-receptor binding interactions, replacing fragments that contribution the least to binding and finally reassembling the fragments to form a new ligand. The fundamental idea is to replace "bad" fragments of a ligand with "good" fragments while leaving the core of the ligand intact, thus improving the compound's activity. The molecular fragments were selected from a collection of 27,417 conformers that are the fragments of compounds in the DrugBank database. The collection of molecular fragments are docked to the target's binding site and evaluated using group efficiency (calculated binding affinity divided by the number of heavy atoms), and the "strongest" binder is selected. The LeadOp method was tested with two biomolecular systems: mutant B-Raf kinase and human 5-lipoxygenase. The LeadOp methodology was able to optimize the query molecules and systematically developed improved analogs for each of our example systems.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21627327     DOI: 10.1021/ci200136j

Source DB:  PubMed          Journal:  J Chem Inf Model        ISSN: 1549-9596            Impact factor:   4.956


  2 in total

1.  A reverse combination of structure-based and ligand-based strategies for virtual screening.

Authors:  Alvaro Cortés-Cabrera; Federico Gago; Antonio Morreale
Journal:  J Comput Aided Mol Des       Date:  2012-03-07       Impact factor: 3.686

2.  LeadOp+R: Structure-Based Lead Optimization With Synthetic Accessibility.

Authors:  Fang-Yu Lin; Emilio Xavier Esposito; Yufeng J Tseng
Journal:  Front Pharmacol       Date:  2018-03-05       Impact factor: 5.810

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.